Alvimopan as a Rescue Treatment of Postoperative Ileus
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the cost effectiveness of Alvimopan as rescue therapy in patients
undergoing colorectal or small bowel resection who develop POI, and its safety and
effectiveness in reducing LOS and POI duration.
This will be a prospective randomized control trial with a total of 58 patients, 29 in each
group. Patients who undergo laparoscopic or open colorectal resection, small bowel resection,
or ileostomy reversal with small bowel resection that subsequently develop postoperative
ileus will be eligible for enrollment. If they meet inclusion/exclusion criteria, they will
be randomized at the time of diagnosis of postoperative ileus to receive Alvimopan as rescue
therapy or to receive conservative standard care.
Patients randomized to the study group will be given a maximum of 3 doses of Alvimopan 12mg
orally, 12 hours apart. Alvimopan will be given from the time of diagnosis of postoperative
ileus to the time of return of bowel function or the maximum 3 doses. Subsequent Alvimopan
doses will be given if there is no return of bowel function or if symptoms of distension
and/or nausea persist despite some return of bowel function.